Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Health care policy. Reforming off-label promotion to enhance orphan disease treatment.

× No keyword cloud information.

14 in total

1. Reforming direct-to-consumer advertising.

Authors: Bryan A Liang; Tim Mackey
Journal: Nat Biotechnol Date: 2011-05 Impact factor: 54.908

Review 2. Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors: Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal: Clin Microbiol Rev Date: 2014-10 Impact factor: 26.132

3. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.

Authors: Martina Bonifazi; Marta Rossi; Lorenzo Moja; Vincenzo Davide Scigliano; Matteo Franchi; Carlo La Vecchia; Carlo Zocchetti; Eva Negri
Journal: Oncologist Date: 2011-12-30

4. Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".

Authors: Tim K Mackey
Journal: Int J Health Policy Manag Date: 2016-02-03

5. Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks.

Authors: Martha M Rumore
Journal: J Pediatr Pharmacol Ther Date: 2016 Jan-Feb

6. Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity.

Authors: Bryan A Liang; Timothy Mackey
Journal: Ther Clin Risk Manag Date: 2011-12-07 Impact factor: 2.423

Review 7. Pharmaceutical pricing, cost containment and new treatments for rare diseases in children.

Authors: Peter Stella; Gabrielle Gold-von Simson
Journal: Orphanet J Rare Dis Date: 2014-10-28 Impact factor: 4.123

8. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.

Authors: Mike Paulden; Tania Stafinski; Devidas Menon; Christopher McCabe
Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981

Review 9. Ethical and legal framework and regulation for off-label use: European perspective.

Authors: Christian Lenk; Gunnar Duttge
Journal: Ther Clin Risk Manag Date: 2014-07-12 Impact factor: 2.423

10. Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.

Authors: Tim K Mackey; Virginia J Schoenfeld
Journal: BMC Med Date: 2016-02-02 Impact factor: 8.775